Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to Earnings
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested Capital

Aura Biosciences (AURA) Enterprise Value (2020 - 2026)

Aura Biosciences filings provide 7 years of Enterprise Value readings, the most recent being -$84.8 million for Q1 2026.

  • Quarterly Enterprise Value fell 121.82% to -$84.8 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$84.8 million through Mar 2026, down 121.82% year-over-year, with the annual reading at -$59.5 million for FY2025, 87.79% down from the prior year.
  • Enterprise Value hit -$84.8 million in Q1 2026 for Aura Biosciences, down from -$59.5 million in the prior quarter.
  • Across five years, Enterprise Value topped out at -$19000.0 in Q4 2023 and bottomed at -$107.4 million in Q2 2025.
  • Average Enterprise Value over 5 years is -$32.4 million, with a median of -$30.1 million recorded in 2024.
  • Peak annual rise in Enterprise Value hit 99.99% in 2022, while the deepest fall reached 305450.0% in 2022.
  • Aura Biosciences' Enterprise Value stood at -$20000.0 in 2022, then increased by 5.0% to -$19000.0 in 2023, then plummeted by 166705.26% to -$31.7 million in 2024, then crashed by 87.79% to -$59.5 million in 2025, then crashed by 42.47% to -$84.8 million in 2026.
  • Per Business Quant, the three most recent readings for AURA's Enterprise Value are -$84.8 million (Q1 2026), -$59.5 million (Q4 2025), and -$47.6 million (Q3 2025).